Trial Profile
Randomized Comparison of Zotarolimus- and Everolimus-Eluting Stents for Coronary Treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ZEPPELIN
- 23 Oct 2008 New trial record.